Duty relief to boost pharma companies' access to UK drug stores

The India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and streamlined regulations will drive growth. Indian companies will gain easier access to the UK market. This will boost exports, especially for generics and biosimilars. The agreement also promotes cross-border research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tSfPBnd
via IFTTT